secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0000950170-23-005699
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics reports Q4 2022 net loss of $18.8M; appoints new CEO and halts preclinical programs
--------------------------------------------------------------------------------

- Cash, equivalents, marketable securities and restricted cash of $57.3M as of Dec 31, 2022; expected to fund operations into Q4 2023.
- Q4 2022 net loss $18.8M vs $20.4M in Q4 2021; full-year net loss $83.8M vs $65.8M in 2021.
- Jeffrey Goldberg appointed president and CEO; Linda Neuman promoted to CMO, Cortney Caudill to chief product officer.
- Pegtarviliase received FDA Fast Track Designation; EMA decision on pegzilarginase MAA expected late 2023.
- Preclinical work on Cystinuria and other pipeline programs halted; company evaluating strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023005699/0000950170-23-005699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023005699/agle-20230302.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer